Home > Back to Publisher > Report Information

Healthcare Reform in China

Business Insights
October 20, 2011
SKU: RET6655531

Abstract Table of Contents Related Reports

Countries covered: China

China's pharmaceutical market is growing rapidly in step with it's wider economy. The government aims to extend healthcare coverage to it's 1.3bn citizens, which will impact multiple corporate stakeholders.

This report gives an overview of China's demographics, overall healthcare infrastructure, and the need for healthcare reforms. It provides detailed coverage of China's healthcare reform plans from the viewpoint of pharmaceutical companies, payers, and healthcare providers. Reforms and implications for various stakeholders are assessed and comments from 23 managers at Chinese hospitals included.

Learn how healthcare is being reformed in China and the effects on various industry stakeholders.

Develop strategies for successful market penetration in China.

Understand the regulatory structures which affect how drugs are approved and reimbursed in China.

Gain insights about the effects of reform from a Scrip Business Insights survey of 23 managers at Chinese hospitals.

Evaluate the importance of tier 2 and 3 cities in China's pharmaceutical market.

Historically, China had a very high out-of-pocket expenditure on healthcare. However, the proportion of out-of-pocket expenditure on healthcare dropped from 60% in 2001 to 40% in 2008 due to the increasing coverage of social health insurance schemes.

>China's population will increase by 85m people between 2010 and 2020. 85% of this will be accounted for by an increase in the population of over 60s, which will prompt growth in markets for cardiovascular diseases, dementia, and other age-linked conditions. A sharp rise in lifestyle diseases such as diabetes and obesity is also underway.

Reforms are set to present opportunities for pharma companies, CROs, medical device manufacturers, and private health insurance providers. Healthcare IT is also set for a boost, as the government begins to invest in electronic health records.

How is healthcare provision in China changing, and how can pharma companies capitalize on this?

How will healthcare reform in China affect CROs and clinical research?

What are the opinions of Chinese hospital managers on the effects of reform?

What are the advantages and disadvantages for a company to have a product listed on the national drug reimbursement lists?

How will medical device manufacturers and private health insurance providers be affected by healthcare reforms?

Please note: this is delivered as a Zip file.

About the author: Disclaimer
EXECUTIVE SUMMARY
China’s changing population: China’s healthcare system and the need for reform; Healthcare reform in China; Implications of reforms for stakeholders; China’s changing population; Summary; Introduction; Increasing population; Aging population; Change in therapeutic focus; The rise of the middle class and increase in spending power; Urbanization; Maximizing the opportunity of smaller city markets
China’s healthcare system and the need for reform: Summary; Overview; History of Chinese healthcare; Regulatory structure and government departments
Organization of healthcare and the hospital system: Urban healthcare; Rural healthcare; Differences in hospital healthcare; Urban healthcare and rural healthcare; Pricing and reimbursement in China; Approving drugs for reimbursement; Traditional Chinese Medicine
Healthcare reform in China: Summary; Universal medical insurance; Basic Medical Insurance; Urban Resident Basic Medical Insurance; New Rural Cooperative Medical Insurance; Private insurance; Assessment of health insurance programs; Drug pricing reform; Essential Drug List; The National Reimbursement Drug List; Hospital reform; Increasing the number of community health clinics; Reform of hospital finance
Implications of reforms for stakeholders: Summary; Introduction; Pharmaceutical companies; Hospitals; Contact research organizations; Medical device companies; Private health insurance companies; Healthcare IT companies; Assessment and conclusion
Appendix: Scope; Methodology; Glossary/Abbreviations; References; Questionnaire responses
TABLES: Table: China’s population composition and projections by age group; Table: China’s urban and rural population (m), 2000-50; Table: Composition of the expenditure for public health in China, 2001-08; Table: Evolution of social medical insurance in China; Table: Overview of China’s healthcare related agencies; Table: Urban and rural levels of healthcare; Table: Statistics on New Rural Cooperative Medical System, 2004-09; Table: Financing Structure of NRCMS in Xiangtan City (RMB), 2005-09; Table: Overview of government subsidised medical insurance programs; Table: Comparison of the top 10 international additions/removals of key drugs, 2004-09; Table: Utilization rate for community health centres, 2002-09; Table: Number of privately owned medical institutions in China, 2008; Table: Six hospital categories covered for the questionnaire
FIGURES: Figure: China’s population growth rate, 1990-2010; Figure: China’s population, 1990-2030; Figure: Diabetes prevalence in China, India, US, UK, and Japan, 2010; Figure: Average wage of employed persons in urban units in China, 1995-2009; Figure: China’s middle class population increase, 2010-15; Figure: China’s urban and rural population (m), 2000-50; Figure: Comparison of healthcare expenditure in the US and China; Figure: Composition of the expenditure for Public Health in China (2001-08); Figure: Lists A and B on the NRDL; Figure: Repositioning of medical institutions; Figure: Decision criteria for pharmaceutical companies to seek listing on NRDL; Figure: Application and approval procedure for clinical trials; Figure: Private health insurance market opportunity in China ($bn), 2008-20

More China Regulation & Policy Reports

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

China Chinese Patent Drug Processing Industry, 2012 by Reports From China
China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese ...

China Drug Patent Inventor Report - 2011 Publication List by DrugPatentWatch
TheChina Drug Patent Inventor Reportprofiles China-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

China Pharmaceutical Equipment Industry Report, 2011-2012 by Research in China
In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales ...

Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 by GBI Research
Emerging Pharmaceutical Market in China - Forecast to Become The World’s Third-Largest Pharmaceutical Market By 2013 Summary GBI Research’s new report, “Emerging Pharmaceutical Market in China - ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Juice – China – a snapshot (2010) by Mintel - Snapshots
Juice in China by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. The report covers packaged ...

See all reports like this >>

Healthcare Reform in China

Share this report

Other tasks

Research Assistance

Related Markets

Regulation & Policy Reports

Free Alert Me service